The level of the pressure in the pulmonary ... A complete appraisal, in physiologic terms, of the mechanism of pulmonary hypertension in heart disease must take into account these three factors ...

Weak: only small or nonrandomized trials available; Unknown: not enough data to determine benefit. ERA: Endothelin receptor antagonist; PDE5: Phosphodiesterase type 5; PH: Pulmonary hypertension.

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

Corvista Health’s point-of-care device, used to predict pulmonary hypertension (PH), also appears to work well at identifying ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension.

Exclusive e-cigarette use is significantly associated with new cases of chronic obstructive pulmonary disease.